MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
4.190
+0.020
+0.48%
After Hours: 4.210 +0.02 +0.48% 19:08 03/01 EST
OPEN
4.160
PREV CLOSE
4.170
HIGH
4.250
LOW
4.150
VOLUME
54.41K
TURNOVER
0
52 WEEK HIGH
7.99
52 WEEK LOW
2.250
MARKET CAP
92.37M
P/E (TTM)
-1.1901
1D
5D
1M
3M
1Y
5Y
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 5d ago
Weekly Report: what happened at DCTH last week (0219-0223)?
Weekly Report · 6d ago
Delcath Systems Announces Healthcare Setting Locator For HEPZATO™ KIT (melphalan/Hepatic Delivery System) On The hepzatokit.com Website
Delcath Systems, Inc. Has launched a Healthcare Setting Locator to identify healthcare settings offering treatment with the HEPZATO KIT. The KIT is a liver-directed treatment for patients with metastatic uveal melanoma. The Company is focused on the treatment of liver cancers of the liver.
Benzinga · 02/22 22:20
12 Health Care Stocks Moving In Monday's After-Market Session
Trexade Health (NASDAQ:MEDS) stock rose 105.3% to $8.5 during Monday's after-market session. Iovance Biotherapeutics shares moved upwards by 32.78% during the session. Virpax Pharmaceuticals and Delcath Systems were the biggest losers in the company.
Benzinga · 02/19 21:30
Weekly Report: what happened at DCTH last week (0212-0216)?
Weekly Report · 02/19 12:11
Delcath Systems Executives Announce Retirement Plans
TipRanks · 02/14 21:12
Delcath Sys: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 03:54
Weekly Report: what happened at DCTH last week (0205-0209)?
Weekly Report · 02/12 11:57
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.